27.12.2012 Views

12th Congress of the European Hematology ... - Haematologica

12th Congress of the European Hematology ... - Haematologica

12th Congress of the European Hematology ... - Haematologica

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Myeloma and o<strong>the</strong>r monoclonal gammopathies -<br />

Clinical II<br />

0671<br />

REDUCED INTENSITY CONDITIONING ALLOGENEIC TRANSPLANTATION IN MULTIPLE<br />

MYELOMA. A SINGLE CENTER EXPERIENCE<br />

G. Marit, 1 A. Schmitt, 1 R. Tabrizi, 1 M. Sauvezie, 1 J.M. Boiron, 2<br />

K. Bouabdallah, 1 A. Pigneux, 1 T. Leguay, 1 M.S. Dilhuydy, 1 V. Frossard, 1<br />

C. Melot, 1 N. Milpied 1<br />

1 CHU Bordeaux, PESSAC; 2 EFSAL, BORDEAUX, France<br />

The role <strong>of</strong> AT is still controversial in <strong>the</strong> management <strong>of</strong> MM<br />

patients. In order to identify factors influencing <strong>the</strong> outcome post graft<br />

we analyzed <strong>the</strong> results <strong>of</strong> RIC AT performed in 45 MM patients <strong>of</strong> our<br />

institution between June 1999 and August 2006. Median interval<br />

between diagnosis and AT was <strong>of</strong> 32 months (range: 7-172). At time <strong>of</strong><br />

AT, median age was 57 years (range: 44-64), 37 patients were considered<br />

as complete (n=2) or partial (n=35) responders. Before AT 13 patients<br />

received only one line ot treatment as <strong>the</strong> 32 o<strong>the</strong>r received two or more<br />

lines <strong>of</strong> treatment. The number <strong>of</strong> autograft before AT was none or one<br />

in 25 cases and two or more in 19 cases. RIC regimen consisted <strong>of</strong> fludarabine<br />

associated with busulfan (n=32), total body irradiation (n=9),<br />

treosulfan (n=2), idarubicine and cytosine arabinoside (n=1) or melphalan<br />

(n=1). In addition 34 patients received ATG. The donor was an HLAidentical<br />

sibling in 30 cases or an unrelated donor in 15 cases (HLA-identical:<br />

11 or HLA mis-match: 4). With a median follow-up <strong>of</strong> 27 months<br />

(range:4-84), 17 patients are alive and 28 are dead. The causes <strong>of</strong> death<br />

were: transplant-related complications (n=13), relapse or progression<br />

(n=14) and secondary malignancy (n=1). The 3-year event free survival<br />

(EFS) and overall survival (OS) from AT were respectively 20±6.9%<br />

(95%CI) and 34±38.4% (95%CI). The complete remission (CR) rate<br />

after AT was 40% for <strong>the</strong> 42 patients who engrafted. The median EFS<br />

duration from AT for patients achieving CR was 31 months (range:3-56).<br />

Univariate analysis showed that obtention <strong>of</strong> CR post-AT and occurrence<br />

<strong>of</strong> chronic GVHD were <strong>the</strong> factors who had a significant impact<br />

on EFS and OS (p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!